They found that both the expression level of leptin and resistin were significantly increased in the HFD group treated with DOX, confirming obesity conditions induced the changes in tissue fatty acid composition to further reduce the therapeutic effect of DOX. The gene discussed is LEP; the disease is obesity disorder.